识别了一组与对Palbociclib和内分泌疗法的抵抗相关的miRNAs小组
Rosalba Torrisi1, Valentina Vaira2,3, Laura Giordano4
1Medical Oncology and Hematology Unit, Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milano, Italy.
International journal of molecular sciences
|February 10, 2024
概括
这项研究确定了与转移性乳腺癌患者接受内分泌治疗和palbociclib.lib治疗反应差相关的特定微RNA (miRNA). 这些发现可能有助于预测早期的进展,并了解抵抗机制.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 激素受体阳性/HER2阴性转移性乳腺癌通常用内分泌疗法 (ET) 和CDK4/6抑制剂 (CDK4/6i) 治疗.
- 预测治疗反应和理解对CDK4/6i的耐药性机制仍然是一个临床挑战.
研究的目的:
- 确定瘤组织中的微RNA (miRNA) 面板,与转移性乳腺癌患者的治疗反应相关.
- 探索这些miRNAs在预测早期进展和理解新兴ET和palbociclib的耐药性的潜力.
主要方法:
- 分析了52名激素受体阳性/HER2阴性转移性乳腺癌患者的瘤组织,这些患者接受了ET和palbociclib治疗.
- 统计分析以确定与无进展生存 (PFS) 显著相关的miRNAs,包括早期进展 (<6个月).
- 多变量分析以确认已识别的miRNAs对PFS的独立影响.
主要成果:
- 七个miRNA显示出与PFS具有统计学意义的负相关性.
- 特定的miRNAs (例如,miR-378e,miR-99b-5p) 与患有早期进展 (<6个月) 的患者的不良结果有关.
- 多变量分析证实,三个miRNA对PFS产生了显著和独立的影响.
结论:
- 一个新的miRNA小组与ET和palbociclib治疗的患者早期进展的可能性增加有关.
- 这些miRNAs可能提供了对CDK4/6抑制剂新抗性的机制的见解.
- 这些发现是探索性的,需要在更大的患者队伍中进行验证.
相关概念视频
01:22MicroRNAs
3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
02:39lncRNA - Long Non-coding RNAs
8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K